Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 11 (8), 473-81

Acquired Resistance to TKIs in Solid Tumours: Learning From Lung Cancer

Affiliations
Review

Acquired Resistance to TKIs in Solid Tumours: Learning From Lung Cancer

D Ross Camidge et al. Nat Rev Clin Oncol.

Abstract

The use of advanced molecular profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease. However, acquired resistance, defined as progression after initial benefit, to targeted therapies inevitably occurs. This Review explores breakthroughs in the understanding and treatment of acquired resistance in NSCLC, focusing on EGFR mutant and ALK rearrangement-positive disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes. Mechanisms of acquired resistance may be pharmacological (that is, failure of delivery of the drug to its target) or biological, resulting from evolutionary selection on molecularly diverse tumours. A number of clinical approaches can maintain control of the disease in the acquired resistance setting, including the use of radiation to treat isolated areas of progression and adding or switching to cytotoxic chemotherapy. Furthermore, novel approaches that have already proven successful include the development of second-generation and third-generation inhibitors and the combination of some of these inhibitors with antibodies directed against the same target. With our increased understanding of the spectrum of acquired resistance, major changes in how we conduct clinical research in this setting are now underway.

Similar articles

See all similar articles

Cited by 237 articles

See all "Cited by" articles

References

    1. Nature. 2009 Dec 24;462(7276):1070-4 - PubMed
    1. Clin Cancer Res. 2006 Nov 1;12(21):6494-501 - PubMed
    1. Lancet Oncol. 2012 Oct;13(10):1011-9 - PubMed
    1. J Clin Oncol. 2012 Mar 10;30(8):863-70 - PubMed
    1. J Clin Oncol. 2010 Jun 20;28(18):3076-83 - PubMed

MeSH terms

Substances

Feedback